Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy.
Cancer Treat Rev. 2024 Nov;130:102831. doi: 10.1016/j.ctrv.2024.102831. Epub 2024 Sep 24.
This review focuses on the immune checkpoint inhibitors (ICIs) in the context of breast cancer (BC) management. These innovative treatments, by targeting proteins expressed on both tumor and immune cells, aim to overcome tumor-induced immune suppression and reactivate the immune system. The potential of this approach is the subject of numerous clinical studies. Here, we explore the key studies and emerging therapies related to ICIs providing a detailed analysis of their specific and combined use in BC treatment.
这篇综述重点关注了在乳腺癌(BC)管理中免疫检查点抑制剂(ICIs)的应用。这些创新性的治疗方法通过靶向肿瘤细胞和免疫细胞表面表达的蛋白,旨在克服肿瘤诱导的免疫抑制并重新激活免疫系统。该方法的潜力是众多临床研究的主题。在这里,我们探讨了与 ICIs 相关的关键研究和新兴疗法,并对它们在 BC 治疗中的单独和联合应用进行了详细分析。